BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors
Executive Summary
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
You may also be interested in...
Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing
Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license or partner assets increased optionality, Inventiv Health's Neel Patel told a session at BIO 2017.
Gene Therapy Reimbursement: Is Blindness A Bad First Test?
The first gene therapy approval could be coming soon – followed shortly by the first ever gene therapy coverage decision. An Express Scripts executive argues that the tone may be affected by the initial indication.
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.